Carnitab330 mg

Carnitab 330 mg is indicated in- Chronic Fatigue Syndrome Heart Diseases Congestive Heart Failure Kidney Disease High Cholesterol Intermittent Claudication Dementia and memory impairment Down Syndrome Male infertility Hyperthyroidism

Drugs for muscular energy metabolism

Carnitab 330 mg is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production in the form of Adenosine Tri phosphate or ATP. Fatty acids are utilized as an energy substrate in all tissues except the brain. In skeletal and cardiac muscle, fatty acids are the main substrate for energy production.

Tablet- Adults: The recommended oral dosage for adults is 990 mg, two or three times a day using the 330 mg tablets, depending on clinical response. Infants and children: The recommended oral dosage for infants and children is between 50 and 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day. The exact dosage will depend on clinical response. Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations and overall clinical condition.Syrup- Adults: 10 to 30 ml/day. Dosage should start at 10 ml/day in divided doses, and be increased slowly while assessing tolerance and therapeutic response. Infants and children: 50 to 100 mg/kg/day which is equivalent to 0.5 ml/kg/day. Dosage should start at 50 mg/kg/day, and be increased slowly to a maximum of 3 g/day (30 ml/day) while assessing tolerance and therapeutic response. Solution may be consumed alone or dissolved in drink or other liquid food. Doses should be spaced evenly throughout the day (every three or four hours) preferably during or following meals and should be consumed slowly in order to maximize tolerance.

Carnitab 330 mg tablet- Adults: 330 mg two or three times daily. Depending on clinical response. Infants and children: 50 to 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day. The exact dosage will depend on clinical response. Carnitab 330 mg solution (For oral use only. Not for parenteral use)- Adults: The recommended dosage of Carnitab 330 mg 100 ml solution is 10 to 30 ml/day. Higher doses should be administered with caution. Dosage should be started at 10 ml/day and be increased slowly while assessing tolerance and therapeutic response. Infants and children: The recommended dosage of Carnitab 330 mg 100 ml solution is 50 to 100 mg/kg/day. Dosage should be started at 50 mg/kg/day and be increased slowly to a maximum of 30 ml. /day. Carnitab 330 mg oral solution can be given from 2-spoonful to 6-spoonful in divided dose as directed by physicians. Higher doses should be administered with caution. Note: Carnitab 330 mg 100 ml solution may be consumed alone or dissolved in drink or other liquid food. Doses should be spaced evenly throughout the day preferably during or following meals and should be consumed slowly in order to maximize tolerance.

Reports of INR increase with the use of warfarin have been observed. It is recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with Carnitab 330 mg or after dose adjustments.

There is no known disease or syndrome in which Carnitab 330 mg administration is contraindicated. It is contraindicated in patients with hypersensitivity to any of its components.

Generally, Carnitab 330 mg is well tolerated. However, few side effects including transient nausea and vomiting, abdominal cramps, and diarrhoea may occur.

Carnitab 330 mg is categorized by the USFDA as Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. Supplemental Carnitab 330 mg should be used by pregnant women only if clearly indicated and only under medical supervision. It is not known whether Carnitab 330 mg is excreted in human milk. Supplemental Carnitab 330 mg is not advised for nursing mothers. Those with seizure disorders should only use Carnitab 330 mg under medical advisement and supervision.

Gastrointestinal reactions may result from a too rapid consumption of Carnitab 330 mg. The safety and efficacy of oral Carnitab 330 mg has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral Carnitab 330 mg in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N oxide (TMAO), since these metabolites are normally excreted in the urine.

There have been no reports of toxicity from Carnitab 330 mg overdosage.

Do not store above 30°C. Keep away from light and out of the reach of children.

Drugs for muscular energy metabolism

Carnitab 330 mg is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production. Fatty acids are utilized as an energy substrate in all tissues except the brain. In skeletal and cardiac muscle, fatty acids are the main substrate for energy production.

There is no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Carnitab 330 mg supplementation in nursing mothers has not been specifically studied. In nursing mothers receiving Carnitab 330 mg, any risks to the child of excess carnitine intake need to be weighed against the benefits of Carnitab 330 mg supplementation to the mother. Consideration may be given to discontinuation of nursing or of Carnitab 330 mg treatment.